Michael E. Thase, M.D. Dr. Thase is an expert in assessment and treatment of mood disorders, with particular interest in major depressive disorders, long-term treatment and combination therapy. His current PI work includes a study of cognitive therapy for depression treatment, a multi-site investigation of psychotherapy and medication in addressing major depression, and a placebo-controlled, randomized clinical trial on the use of continuation-phase cognitive therapy and fluoxetine for major depressive disorder. In addition, Dr. Thase is editor-in-chief of Psychopharmacology Bulletin.

Positions

• Professor of Psychiatry, University of Pittsburgh Medical Center; Western Psychiatric Institute and Clinic

Education

• M.D., 1979, Ohio State University

Relevant Publications

• Thase ME. Preventing relapse and recurrence of depression: A brief review of therapeutic options. CNS Spectrums. 2006;11(Suppl 15):12-21.
• Thase ME. New directions in the treatment of atypical depression. J Clin Psychiatry. 2006;67.
• Thase ME. The failure of evidence-based medicine to guide treatment of antidepressant nonresponders. J Clin Psychiatry. 2006;67:1833-1835.
• Thase ME. Treatment-resistant depression and the bipolar spectrum: Recognition and management. Primary Psychiatry. 2006;13:59-67.
• Thase ME, Clayton AH, Haight BR, Thompson AH, Modell JG, Johnston JA. A double-blind comparison between Bupropion XL and Venlafaxine XR: Sexual functioning, antidepressant efficacy, and tolerability. J Clin Psychopharmacol. 2006;26:482-488.
• Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: A double-blind, placebo-controlled study (The BOLDER II Study). J Clin Psychopharmacol. 2006;26: 600-609.

Contributed Content

• Becoming an Effective Employer
• Co-PI Relationships
• Funding Large Studies
• Have Your Eyes Open
• Staying in Touch with the Project
• The Bigger Picture
• Two Career Diversions
• University Peer Review